IE
AUTL

Israel Englander’s Autolus Therapeutics AUTL Stock Holding History

Israel Englander’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.96M Buy
1,224,818
+1,020,090
+498% +$1.6M ﹤0.01% 3840
2026
Q1 		$283K Buy
+204,728
New +$311K ﹤0.01% 5033
2025
Q4 		– Sell
-391,833
Closed -$639K – 6001
2025
Q3 		$639K Buy
+391,833
New +$765K ﹤0.01% 4927
2025
Q2 		– Sell
-1,986,190
Closed -$3.08M – 5845
2025
Q1 		$3.08M Buy
1,986,190
+332,949
+20% +$676K ﹤0.01% 3364
2024
Q4 		$3.89M Buy
1,653,241
+790,437
+92% +$2.67M ﹤0.01% 3054
2024
Q3 		$3.13M Buy
862,804
+49,773
+6% +$198K ﹤0.01% 3258
2024
Q2 		$2.83M Buy
813,031
+432,503
+114% +$1.87M ﹤0.01% 3221
2024
Q1 		$2.43M Buy
380,528
+319,798
+527% +$1.99M ﹤0.01% 3562
2023
Q4 		$391K Buy
+60,730
New +$232K ﹤0.01% 4796
2023
Q2 		– Sell
-360,145
Closed -$663K – 6096
2023
Q1 		$663K Buy
360,145
+234,495
+187% +$458K ﹤0.01% 4426
2022
Q4 		$239K Buy
125,650
+46,640
+59% +$118K ﹤0.01% 5227
2022
Q3 		$169K Sell
79,010
-158,649
-67% -$470K ﹤0.01% 5750
2022
Q2 		$673K Buy
237,659
+70,093
+42% +$213K ﹤0.01% 4720
2022
Q1 		$699K Sell
167,566
-142,758
-46% -$600K ﹤0.01% 4860
2021
Q4 		$1.61M Sell
310,324
-133,107
-30% -$799K ﹤0.01% 3963
2021
Q3 		$2.9M Sell
443,431
-281,741
-39% -$1.78M ﹤0.01% 3472
2021
Q2 		$4.82M Buy
725,172
+496,663
+217% +$3.08M ﹤0.01% 2809
2021
Q1 		$1.31M Buy
228,509
+197,636
+640% +$1.46M ﹤0.01% 3941
2020
Q4 		$276K Sell
30,873
-117,447
-79% -$1.25M ﹤0.01% 4606
2020
Q3 		$1.73K Sell
148,320
-578,521
-80% -$8.39M ﹤0.01% 2711
2020
Q2 		$11.7M Sell
726,841
-56,323
-7% -$625K 0.02% 1115
2020
Q1 		$4.69M Buy
783,164
+106,683
+16% +$986K 0.01% 1376
2019
Q4 		$8.93M Sell
676,481
-719,661
-52% -$9.42M 0.01% 1467
2019
Q3 		$17.3M Buy
1,396,142
+628,306
+82% +$8.3M 0.03% 878
2019
Q2 		$12.4M Buy
767,836
+317,474
+70% +$7.1M 0.02% 1100
2019
Q1 		$14.2M Buy
450,362
+438,662
+3,749% +$12.5M 0.02% 1025
2018
Q4 		$384K Sell
11,700
-24,258
-67% -$798K ﹤0.01% 3107
2018
Q3 		$1.08M Sell
35,958
-109,987
-75% -$2.97M ﹤0.01% 2831
2018
Q2 		$3.91M Buy
+145,945
New +$3.86M 0.01% 1962

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Israel Englander's AUTL Position: Q2 2026 in Review

Israel Englander increased its Autolus Therapeutics (AUTL) stake by 498% in Q2 2026, buying an estimated $1.6M and bringing the position to 1,224,818 shares worth $1.96M. The position accounts for ﹤0.01% of the portfolio, ranked #3840.

Israel Englander first reported a position in AUTL in Q2 2018 and has held it in 29 quarters since. The position peaked at $17.3M in Q3 2019. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Israel Englander held 1,224,818 shares of Autolus Therapeutics worth $1.96M as of Q2 2026.
  • Israel Englander bought 1,020,090 Autolus Therapeutics shares in Q2 2026, an estimated $1.6M.
  • Autolus Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3840 holding.
  • Israel Englander first reported a position in Autolus Therapeutics in Q2 2018 and has held it in 29 quarters since.
  • Israel Englander's Autolus Therapeutics position peaked at $17.3M in Q3 2019.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.